Tamoxifen is not for all women, but in women with an elevated risk of breast cancer, should be discussed as a prevention measure. Raloxifene is now being compared to Tamoxifen in a trial called the STAR trial. This is being sponsored by the National Cancer Institute trial. Moffitt Cancer Center is the nearest institution enrolling women with an elevated risk of breast cancer. Call them for information on the trial if you are interested in being a participant.
Breast cancer is the most common cancer in women.
This is the bad news. The commonest cancer in women can be detected early and has a good chance of cure with early detection. Surgical treatment is becoming less aggressive, but maintaining good results. There are effective chemotherapy agents which improve the odds of cure even further. The development of breast cancer can be reduced in women at higher than average risk for the disease by taking Tamoxifen.